Purchase Order 75F40124P00121
Award Date 4/4/24
Potential Completion Date 4/24/25
Potential Value $219K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
- The Food and Drug Administration awarded a $439,247.56 firm fixed-price purchase order to Illumina, Inc. on July 15, 2024, for the procurement of an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System. The award encompasses the sequencing instrument itself, trade-in credit for an existing NextSeq 500 unit, installation services, operator training, warranty coverage, and a preventative maintenance agreement. The system will be delivered to and installed at the FDA's Center for...
- This firm fixed-price purchase order contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing technologies. The $576,928.00 contract is for the procurement of an Illumina NextSeq2000 Sequencing System, including associated reagents and maintenance services. The contract has a period of performance through July 20, 2026. Illumina is a key technology provider for federal scientific and diagnostic...
- The Food and Drug Administration awarded a $233.7K firm fixed-price purchase order to Illumina, Inc. for an Illumina NextSeq 2000 Sequencing System plus one option year of post-warranty maintenance. The award was issued on June 17, 2024, with an ultimate completion date of July 23, 2026. The equipment will be delivered to and maintained at the FDA's National Center for Toxicological Research in Jefferson, Arkansas, though the place of performance is listed as Singapore. No set-aside...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- The Food and Drug Administration awarded a $996,000 firm fixed-price delivery order to Illumina, Inc. for a MiSeq Sequencer and associated reagents on September 15, 2014, with an ultimate completion date of September 13, 2017. The award was issued to the San Diego-based biotechnology company without set-aside designation, reflecting Illumina's specialized position as the primary provider of next-generation DNA and RNA sequencing technologies to federal agencies. The delivery order procures...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The $114,681.00 contract is for the delivery of a MiSeq System, a high-throughput next-generation DNA sequencing platform used to support life science research, applied markets, and molecular diagnostics. This award does not have a set-aside designation. Illumina has a history of providing...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for the provision of a next generation sequencer. The contract has a potential value of $100,980.00 and a completion date of August 28, 2020. Illumina has provided similar sequencing systems and consumables to support genomic research and diagnostics across various federal agencies such as the National...
- The Department of Health and Human Services Food and Drug Administration awarded a $169,505.48 firm fixed price purchase order to Illumina, Inc. of Laurel, Maryland for an Illumina NextSeq 50 System Check. The contract has a period of performance through February 10, 2025 to deliver product care services for the NextSeq 50 sequencing system. No set-aside provisions were applied to this award made by the FDA to support its regulatory and public health responsibilities through genomic analysis...
- This contract is for the acquisition of the NEXTSEQ 2000 SEQUENCING SYSTEM by the Department of Health and Human Services Food and Drug Administration. The $432,031.00 firm fixed price contract was awarded to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract has a completion date of November 12, 2025 and does not have a set-aside designation. Illumina has previously been awarded prime contracts by federal agencies such as the...